Search results
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 11 hours agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Cantor Fitzgerald Brokers Boost Earnings Estimates for Merck & Co., Inc. (NYSE:MRK)
ETF DAILY NEWS· 2 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings per share (EPS) estimates for ...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
KFGO· 7 days agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Merck reports promising V116 vaccine trial results By Investing.com
Investing.com· 3 days agoMerck & Co. (NYSE: MRK) has presented new data from its Phase 3 STRIDE-10 trial of V116, an...
Merck & Co., Inc. (NYSE:MRK) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Simply Wall St. via Yahoo Finance· 5 days agoMerck & Co., Inc. (NYSE:MRK) just released its quarterly report and things are looking bullish. The...
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Proactive Investors· 7 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after...
MRK Stock Sees Surge of Approximately 1.30% in Last Five Days – Knox Daily
Knox Daily· 7 days agoInvestors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Merck & Co Inc shares valued at $492,135,715 ...
Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
Bloomberg· 7 days agoMerck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda...
Merck Raises 2024 Profit Forecast on Strong Sales of Cancer Drug Keytruda
US News & World Report· 7 days agoKeytruda, the world's top selling drug in 2023, has been Merck's key revenue driver over the past few years and is expected to top $30 billion in sales by 2026 before losing exclusivity toward ...